Why is Boston Scientific stock plunging today?
Boston Scientific (BSX) stock fell 11.9% in pre-market trading after its Q3 2026 results. The company reported adjusted EPS of $0.73, missing estimates, and lowered its Q4 and full-year 2026 guidance due to a cyberattack and competitive pressures. Net sales grew 1.5% YoY to $5.14B, slightly beating expectations. The stock neared its 52-week low.
How this was made
The 30-second read
Why it matters
The guidance reduction and margin decline are likely to keep the stock under pressure, especially given the 11.9% pre‑market drop.
Market read
The earnings miss and guidance cut triggered a sharp sell‑off, making the news highly relevant for short‑term traders.
What to watch
Potential cost‑saving measures or insurance recoveries from the cyber incident are not yet quantified.
Background
Boston Scientific disclosed Q3 results with modest revenue beat but missed EPS expectations and cut guidance, attributing the slowdown to a recent cyberattack and competitive pressure.
Ticker impact
Boston Scientific reported Q3 earnings miss and cut full-year guidance, causing an 11.9% pre‑market plunge.
likely further decline as investors price in lower EPS forecasts and cyberattack fallout
The earnings miss, sharp margin contraction, and reduced EPS outlook are fresh, material facts that moved the stock sharply.
Market effects
Medical device sector may see broader pressure as competitors gain share while Boston Scientific grapples with cyber‑attack disruptions.
U.S. equities could open lower, especially health‑care stocks, following the sharp move in BSX.
Limited to U.S. markets; no immediate global macro impact.
Counterpoint
If the cyberattack impact is overstated, the stock could rebound on a short‑cover rally.
Key entities
- CompanyBoston Scientific
Medical device maker reporting Q3 2026 earnings.
